The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cells

Biochemical and Biophysical Research Communications

Volumn 357, Issue 2, 2007, Pages 341-346

  Chuu, Chih pin ^a   Chen, Rou Yu ^b   Hiipakka, Richard A ^a   Kokontis, John M ^a   Warner, Karen V ^a   Xiang, Jialing ^b   Liao, Shutsung ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b ILLINOIS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Androgen; Antiandrogen; AR; LNCaP; LXR agonist; PSA; T0901317

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; HYDROXYFLUTAMIDE; METRIBOLONE; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; PROSTATE SPECIFIC ANTIGEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN LNCAP; COMPARATIVE STUDY; CONTROLLED STUDY; EMBRYO; GENE EXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; ISOTOPE LABELING; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; REPORTER GENE;

ANGIOGENESIS INHIBITORS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SULFONAMIDES;

EID: 34247153122     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.03.116     Document Type: Article

References (38)

1. Song C., Kokontis J.M., Hiipakka R.A., and Liao S. Ubiquitous receptor: a receptor that modulates gene activation by retinoic acid and thyroid hormone receptors. Proc. Natl. Acad. Sci. USA 91 (1994) 10809-10813
2. Shinar D.M., Endo N., Rutledge S.J., Vogel R., Rodan G.A., and Schmidt A. NER, a new member of the gene family encoding the human steroid hormone nuclear receptor. Gene 147 (1994) 273-276
3. Janowski B.A., Willy P.J., Devi T.R., Falck J.R., and Mangelsdorf D.J. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 383 (1996) 728-731
4. Forman B.M., Ruan B., Chen J., Schroepfer Jr. G.J., and Evans R.M. The orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolism. Proc. Natl. Acad. Sci. USA 94 (1997) 10588-10593
5. Lehmann J.M., Kliewer S.A., Moore L.B., Smith-Oliver T.A., Oliver B.B., Su J.L., Sundseth S.S., Winegar D.A., Blanchard D.E., Spencer T.A., and Willson T.M. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 272 (1997) 3137-3140
6. Song C., and Liao S. Cholestenoic acid is a naturally occurring ligand for liver X receptor alpha. Endocrinology 141 (2000) 4180-4184
7. Schultz J.R., Tu H., Luk A., Repa J.J., Medina J.C., Li L., Schwendner S., Wang S., Thoolen M., Mangelsdorf D.J., Lustig K.D., and Shan B. Role of LXRs in control of lipogenesis. Genes Dev. 14 (2000) 2831-2838
8. Collins J.L., Fivush A.M., Watson M.A., Galardi C.M., Lewis M.C., Moore L.B., Parks D.J., Wilson J.G., Tippin T.K., Binz J.G., Plunket K.D., Morgan D.G., Beaudet E.J., Whitney K.D., Kliewer S.A., and Willson T.M. Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J. Med. Chem. 45 (2002) 1963-1966
9. Cao G., Liang Y., Broderick C.L., Oldham B.A., Beyer T.P., Schmidt R.J., Zhang Y., Stayrook K.R., Suen C., Otto K.A., Miller A.R., Dai J., Foxworthy P., Gao H., Ryan T.P., Jiang X.C., Burris T.P., Eacho P.I., and Etgen G.J. Antidiabetic action of a liver X receptor agonist mediated by inhibition of hepatic gluconeogenesis. J. Biol. Chem. 278 (2003) 1131-1136
10. Terasaka N., Hiroshima A., Koieyama T., Ubukata N., Morikawa Y., Nakai D., and Inaba T. T0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 536 (2003) 6-11
11. Blaschke F., Leppanen O., Takata Y., Caglayan E., Liu J., Fishbein M.C., Kappert K., Nakayama K.I., Collins A.R., Fleck E., Hsueh W.A., Law R.E., and Bruemmer D. Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries. Circ. Res. 95 (2004) 110-123
12. Efanov A.M., Sewing S., Bokvist K., and Gromada J. Liver X receptor activation stimulates insulin secretion via modulation of glucose and lipid metabolism in pancreatic beta-cells. Diabetes 53 (2004) S75-S78
13. Walcher D., Kummel A., Kehrle B., Bach H., Grub M., Durst R., Hombach V., and Marx N. LXR activation reduces proinflammatory cytokine expression in human CD4-positive lymphocytes. Arterioscler Thromb. Vasc. Biol. 26 (2006) 1022-1028
14. Koldamova R.P., Lefterov I.M., Staufenbiel M., Wolfe D., Huang S., Glorioso J.C., Walter M., Roth M.G., and Lazo J.S. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J. Biol. Chem. 280 (2005) 4079-4088
15. Fukuchi J., Kokontis J.M., Hiipakka R.A., Chuu C.-P., and Liao S. Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells. Cancer Res. 64 (2004) 7686-7689
16. Santos A.F., Huang H., and Tindall D.J. The androgen receptor: a potential target for therapy of prostate cancer. Steroids 69 (2004) 79-85
17. Huggins C., Steven R.E., and Hodges C.V. Studies on prostatic cancer. Arch. Sug. 43 (1941) 209-223
18. Hellerstedt B.A., and Pienta K.J. The current state of hormonal therapy for prostate cancer. CA Cancer J. Clin. 52 (2002) 154-179
19. Kokontis J., Takakura K., Hay N., and Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res. 54 (1994) 1566-1573
20. Kokontis J.M., Hay N., and Liao S. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol. Endocrinol. 12 (1998) 941-953
21. Kokontis J.M., Hsu S., Chuu C.-P., Dang M., Fukuchi J., Hiipakka R.A., and Liao S. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Prostate 65 (2005) 287-298
22. Umekita Y., Hiipakka R.A., Kokontis J.M., and Liao S. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc. Natl. Acad. Sci. USA 93 (1996) 11802-11807
23. Chuu C.-P., Hiipakka R.A., Fukuchi J., Kokontis J.M., and Liao S. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res. 65 (2005) 2082-2084
24. Chuu C.-P., Hiipakka R.A., Kokontis J.M., Fukuchi J., Chen R.-Y., and Liao S. Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist. Cancer Res. 66 (2006) 6482-6486
25. Linja M.J., Savinainen K.J., Saramaki O.R., Tammela T.L., Vessella R.L., and Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 61 (2001) 3550-3555
26. Ford III O.H., Gregory C.W., Kim D., Smitherman A.B., and Mohler J.L. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J. Urol. 170 (2003) 1817-1821
27. Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer. 1 (2001) 34-45
28. Rago R., Mitchen J., and Wilding G. DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled water. Anal. Biochem. 191 (1990) 31-34
29. Kirschmeier P.T., Housey G.M., Johnson M.D., Perkins A.S., and Weinstein I.B. Construction and characterization of a retroviral vector demonstrating efficient expression of cloned cDNA sequences. DNA 7 (1988) 219-225
30. Chen C.A., and Okayama H. Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA. Biotechniques 6 (1988) 632-638
31. Fukuchi J., Hiipakka R.A., Kokontis J.M., Hsu S., Ko A.L., Fitzgerald M.L., and Liao S. Androgenic suppression of ATP-binding cassette transporter A1 expression in LNCaP human prostate cancer cells. Cancer Res. 64 (2004) 7682-7685
32. Gelmini S., Tricarico C., Petrone L., Forti G., Amorosi A., DedolaL G.L., Serio M., Pazzagli M., and Orlando C. Real-time RT-PCR for the measurement of prostate-specific antigen mRNA expression in benign hyperplasia and adenocarcinoma of prostate. Clin. Chem. Lab. Med. 41 (2003) 261-265
33. Liao S., Witte D., Schilling K., and Chang C. The use of a hydroxylapatite-filter steroid receptor assay method in the study of the modulation of androgen receptor interaction. J. Steroid. Biochem. 20 (1984) 11-17
34. Veldscholte J., Ris-Stalpers C., Kuiper G.G., Jenster G., Berrevoets C., Claassen E., van Rooij H.C., Trapman J., Brinkmann A.O., and Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 173 (1990) 534-540
35. Kokontis J., Ito K., Hiipakka R.A., and Liao S. Expression and function of normal and LNCaP androgen receptors in androgen-insensitive human prostatic cancer cells. Altered hormone and antihormone specificity in gene transactivation. Receptor 1 (1991) 271-279
36. Yeung F., Li X., Ellett J., Trapman J., Kao C., and Chung L.W. Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. J. Biol. Chem. 275 (2000) 40846-40855
37. Houck K.A., Borchert K.M., Hepler C.D., Thomas J.S., Bramlett K.S., Michael L.F., and Burris T.P. T0901317 is a dual LXR/FXR agonist. Mol. Genet. Metab. 83 (2004) 184-187
38. Liu Y., Yan C., Wang Y., Nakagawa Y., Nerio N., Anghel A., Lutfy K., and Friedman T.C. Liver X receptor agonist T0901317 inhibition of glucocorticoid receptor expression in hepatocytes may contribute to the amelioration of diabetic syndrome in db/db mice. Endocrinology 147 (2006) 5061-5068